Therapeutic monoclonal antibodies to CGRP such as fremanezumab have been developed because of the very high target specificity, long pharmacokinetic half-lives, and markedly low potential for hepatic toxicity [8, 13] and in phase 2 and 3 clinical studies, fremanezumab was shown to be an effective and safe migraine treatment [8, 14, 15]. The gene discussed is CALCA; the disease is migraine disorder.